AbbVie: Why I Sold My Shares At $175
Summary: We recently sold our ABBV shares at $175. The stock has reached our target
Summary: We recently sold our ABBV shares at $175. The stock has reached our target
Summary: AbbVie Inc. will announce its Q2 2024 earnings next Thursday, 25th July. The company
Summary: AbbVie continues to navigate Humira’s LOE brilliantly, with the higher rebates and lower pricing ensuring its market-leading share
Summary: AbbVie reported first quarter results and although results were not great, the company managed
Summary: AbbVie’s weak stock price performance in the past quarter is in no way an
Summary: AbbVie stock has fallen into a correction, declining nearly 16% from its March 2024
Summary: AbbVie’s recent stock decline is a classic example of how valuation can greatly influence
Summary: AbbVie Inc.’s shares dropped last week due to concerns about the erosion of Humira
Summary: On April 26, AbbVie published financial results for the first quarter of 2024, which
Summary: AbbVie’s Q1 earnings beat estimates, with a smaller decline in Humira sales than expected.